Satsuma Pharmaceuticals, Inc. STSA
1.10 +1.10
Day range unavailable
52-week range unavailable
News
prnewswire.com Satsuma Pharmaceuticals Announces Presentation of Two Clinical Program Abstracts at the American Headache Society's 68th Annual Scientific Meeting DURHAM, N.C., June 4, 2026 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc., a biopharmaceutical company focused on advancing innovative treatments for people living with migraine, today announced that…
prnewswire.com Satsuma Pharmaceuticals and SNBL Announce Publication of Impression of Use and Satisfaction with STS101 (Dihydroergotamine Nasal Powder (Atzumi™)) in Headache Results show that participant impression through 12 months of treatment indicate STS101 is perceived as favorable across multiple attributes. Exploratory Efficacy Endpoints showed that STS101…
prnewswire.com Satsuma Pharmaceuticals and SNBL Announce Four Abstracts to be Presented at the American Headache Society's 67th Annual Scientific Meeting DURHAM, N.C. , June 19, 2025 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to bringing novel treatments to people who suffer from migraine and other…
prnewswire.com Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine Atzumi™ (dihydroergotamine(DHE)) nasal powder is the first and only DHE nasal powder for the acute treatment of migraine with or without aura in adults in an easy-to-use, easy-to-carry device. Atzumi…
prnewswire.com Satsuma Pharmaceuticals and SNBL Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine With or Without Aura DURHAM, N.C. , Nov. 26, 2024 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company, and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd.
prnewswire.com Satsuma Pharmaceuticals and SNBL Resubmits the New Drug Application for STS101 (Dihydroergotamine Nasal Powder) for the Acute Treatment of Migraine With or Without Aura DURHAM, N.C. , Oct. 30, 2024 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company, and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd.
prnewswire.com Satsuma Pharmaceuticals and SNBL Announce Publication of STS101 (Dihydroergotamine Nasal Powder) Pivotal Phase 3 ASCEND Study in CNS Drugs Study shows the repeated long-term, as-needed use of STS101 for the acute treatment of a migraine attack demonstrated a favorable safety profile and was well tolerated. Exploratory Efficacy Endpoints…
prnewswire.com Satsuma Pharmaceuticals and SNBL Announce Five Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society's 66th Annual Scientific Meeting DURHAM, N.C. , June 13, 2024 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for…
benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2023 
benzinga.com Gold Drops Below $2,000; Charles Schwab Earnings Top Views U.S. stocks traded mostly flat midway through trading, following the release of economic data. The Dow traded up 0.01% to 33,890.03 while the NASDAQ fell 0.18% to 12,101.34. The S&P 500, also fell,…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session 
benzinga.com Why Universal Electronics Shares Are Trading Lower By 30%? Here Are Other Stocks Moving In Friday's Mid-Day Session Gainers Ibio Inc (NYSE: IBIO) shares rose 97% to $1.4787 after the company announced MUC16 as its latest immune-oncology target program.
pennystocks.com Best Penny Stocks To Buy Now? 7 Insider Picks In November 7 penny stock picks from insiders in November 2022 The post Best Penny Stocks To Buy Now? 7 Insider Picks In November appeared first on Penny Stocks to Buy, Picks, News and Information |…
pennystocks.com Penny Stocks To Buy: 7 Insider Picks For November 2022 Penny stocks to buy according to insiders in November 2022. The post Penny Stocks To Buy: 7 Insider Picks For November 2022 appeared first on Penny Stocks to Buy, Picks, News and Information |…
investorplace.com Why Is Satsuma Pharmaceuticals (STSA) Stock Down 80% Today? The focus in the world of drugmakers is on Satsuma Pharmaceuticals (NASDAQ: STSA ) right now, but not in a good way. Specifically, the company's proposed treatment for migraine headaches didn't meet…
globenewswire.com Satsuma Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference South San Francisco, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE)…
benzinga.com Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From Friday Gainers
benzinga.com This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade.
globenewswire.com Satsuma Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference SOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal…- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 111 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's session, 35 companies made new 52-week lows.
globenewswire.com Satsuma Pharmaceuticals to Present at the Virtual 11th Annual SVB Leerink Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE)…
globenewswire.com Satsuma Pharmaceuticals Announces the Appointment of Mutya Harsch to its Board of Directors SOUTH SAN FRANCISCO, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE)…
globenewswire.com Satsuma Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE)…
globenewswire.com Satsuma Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE)…
globenewswire.com Satsuma Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Business Highlights - Initiated STS101 SUMMIT Phase 3 efficacy trial; topline results expected second half 2022-
globenewswire.com Satsuma Pharmaceuticals to Present at SVB Leerink's CNS Forum SOUTH SAN FRANCISCO, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE)…
pulse2.com STSA Stock Price Increases Over 15% Pre-Market: Why It Happened The stock price of Satsuma Pharmaceuticals Inc (NASDAQ: STSA) increased by over 15% pre-market. This is why it happened.
benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's morning trading, 129 companies set new 52-week lows. Areas of Interest: The largest company in terms of market cap to set a new 52-week low was Wells Fargo (NYSE: WFC).- benzinga.com Stocks That Hit 52-Week Lows On Thursday Before 10 a.m. ET on Thursday, 23 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Thursday Before 10 a.m. ET Thursday, 132 stocks made new 52-week lows.- benzinga.com 56 Biggest Movers From Friday Gainers Nano-X Imaging Ltd. (NASDAQ: NNOX) shares gained 32.9% to close at $64.19. Nano X Imaging recently announced it has signed an agreement with SPI Medical for the deployment of 630 Nanox.ARC…
- benzinga.com Benzinga's Top Upgrades, Downgrades For July 27, 2020 Upgrades
- benzinga.com Stocks That Hit 52-Week Highs On Tuesday On Tuesday, 154 stocks made new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Monday
- benzinga.com Stocks That Hit 52-Week Highs On Wednesday
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday